Hypnogen

Zolpidem, the active ingredient in Hypnogen, is a non‑benzodiazepine hypnotic presented as an oral tablet for oral use. It is indicated for short‑term treatment of insomnia in adults who have difficulty falling or staying asleep.

GNH USA supplies Hypnogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zolpidem acts on the central nervous system to facilitate sleep in patients with transient insomnia.

- Insomnia (short‑term treatment): Improves sleep onset and maintenance in adults experiencing temporary difficulty falling or staying asleep.

Zolpidem may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness or fatigue - Dizziness or light‑headedness - Headache - Nausea or gastrointestinal discomfort - Unpleasant taste in the mouth - Memory impairment or amnesia

Serious or Rare Side Effects: - Complex sleep‑related behaviors (e.g., sleepwalking, driving while asleep) - Allergic reactions such as rash, itching, or swelling - Depression or mood changes - Respiratory depression in susceptible individuals - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Before prescribing Zolpidem, clinicians should consider several safety factors.

- Assess sleep disorder: Confirm diagnosis of short‑term insomnia before use. - Evaluate hepatic function: Dose may need adjustment in patients with liver impairment. - Review concomitant CNS depressants: Avoid additive sedation with alcohol or other sedatives. - Monitor elderly patients: Increased risk of falls, confusion, and next‑day impairment. - Avoid abrupt discontinuation: Taper if long‑term use has occurred to reduce rebound insomnia. - Store at ambient temperature: Keep below 25 °C in the original container, protected from moisture and direct sunlight.

Zolpidem can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase zolpidem plasma levels. - Other central nervous system depressants (e.g., opioids, barbiturates): Heighten risk of profound sedation and respiratory depression.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce therapeutic effect. - Antidepressants with serotonergic activity (e.g., SSRIs, SNRIs): Potential for increased sleep disturbances. - Antihistamines and anticholinergics: May amplify drowsiness and cognitive impairment.